AU2022295164A1 - Cyclosporine formulations for use in patients undergoing cataract surgery - Google Patents

Cyclosporine formulations for use in patients undergoing cataract surgery Download PDF

Info

Publication number
AU2022295164A1
AU2022295164A1 AU2022295164A AU2022295164A AU2022295164A1 AU 2022295164 A1 AU2022295164 A1 AU 2022295164A1 AU 2022295164 A AU2022295164 A AU 2022295164A AU 2022295164 A AU2022295164 A AU 2022295164A AU 2022295164 A1 AU2022295164 A1 AU 2022295164A1
Authority
AU
Australia
Prior art keywords
hco
cyclosporine
formulation
weight
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022295164A
Other languages
English (en)
Inventor
John HOVANESIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of AU2022295164A1 publication Critical patent/AU2022295164A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022295164A 2021-06-14 2022-06-13 Cyclosporine formulations for use in patients undergoing cataract surgery Pending AU2022295164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202479P 2021-06-14 2021-06-14
US63/202,479 2021-06-14
PCT/IB2022/055462 WO2022264006A1 (en) 2021-06-14 2022-06-13 Cyclosporine formulations for use in patients undergoing cataract surgery

Publications (1)

Publication Number Publication Date
AU2022295164A1 true AU2022295164A1 (en) 2024-01-25

Family

ID=82321536

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022295164A Pending AU2022295164A1 (en) 2021-06-14 2022-06-13 Cyclosporine formulations for use in patients undergoing cataract surgery

Country Status (5)

Country Link
US (1) US20250009837A1 (https=)
EP (1) EP4355301A1 (https=)
JP (1) JP2024521968A (https=)
AU (1) AU2022295164A1 (https=)
WO (1) WO2022264006A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747455C2 (ru) * 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
WO2025163677A1 (en) * 2024-01-31 2025-08-07 Registrar, Panjab University, Chandigarh Nanomicellar composition for high permeation and extended-release drug delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009144186A (ru) * 2007-05-04 2011-06-10 Аллерган, Инк. (Us) Применение циклоспоринов при лечении пациентов с интраокулярными линзами
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения

Also Published As

Publication number Publication date
EP4355301A1 (en) 2024-04-24
US20250009837A1 (en) 2025-01-09
WO2022264006A1 (en) 2022-12-22
JP2024521968A (ja) 2024-06-04

Similar Documents

Publication Publication Date Title
US12569452B2 (en) Ophthalmic compositions comprising F6H8
US20220125783A1 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
AU2020266339B2 (en) Dissolvable polymeric eye inserts and method of using same
CN115066232B (zh) 用于治疗眼病的组合物和方法
JP2022505950A (ja) 老眼、散瞳、および他の眼障害の治療のための方法および組成物
JP6994061B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2012528888A (ja) 眼科用配合剤、その製造方法およびその使用方法
BR112020021845A2 (pt) tratamentos para presbiopia
US20250009837A1 (en) Cyclosporine formulations for use in patients undergoing cataract surgery
Dieleman et al. Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery
JP2022508715A (ja) 緑内障および関連状態の処置のための方法および組成物
US20230372236A1 (en) Drug containing dissolvable ocular inserts and method of using same
Solish et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures
KR20120058588A (ko) 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
Nanda et al. A comparison of efficacy of Nepafenac 0.1% with Nepafenac 0.3% drops for the management of post-operative inflammation and CME in uneventful phacoemulsification
Cruz et al. Postoperative safety outcomes in patients undergoing routine phacoemulsification cataract surgery with intraoperative intracameral injection of preservative-free moxifloxacin versus levofloxacin
US20230338540A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
US20260083720A1 (en) Childhood Atropine For Myopia Progression
WO2025169089A1 (en) Ophthalmic compositions of tyrosine kinase inhibitors and their uses
Michaud et al. Measurement of the Retention Time of Two Different Carbomer‐Based Ophthalmic Gels With and Without Hyaluronic Acid in Anesthetized Dogs Using Ultrahigh‐Resolution Optical Coherence Tomography
Kocamış et al. The Effect of 0.1% Nevanac on Macular Thickness and Volume after Uncomplicated Cataract Surgery
KR20260057219A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형